Pfizer Inc.
NYSE:PFEDrug Manufacturers - General
-$0.71 today
- Market cap
- $159.94B
- Beta
- 0.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.32
- Dividend yield
- 6.82%
Volume 37.37M
Average 36.66M
PFE Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Pfizer Inc.NYSE: PFE
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow turns positive
Q2 FY2026 free cash flow was $302M, compared with -$1.2B a year earlier. Trailing-twelve-month free cash flow was $10.99B. Over 3 fiscal years it compounded at -29.6% a year.
Context
- Free cash flow amounted to 14.5% of revenue in FY2025, down 1.0 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly free cash flow holds near $302M or moves back toward the trailing-twelve-month quarterly average of $2.75B.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 9.08B USD
- Year-over-year change
- -7.7%
- 4-year CAGR
- -25.8%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.08B | -7.7% |
| FY2024 | 2024-12-31 | 9.84B | +105.2% |
| FY2023 | 2023-12-31 | 4.79B | -81.6% |
| FY2022 | 2022-12-31 | 26.03B | -12.8% |
| FY2021 | 2021-12-31 | 29.87B | — |
Free Cash Flow vs competitors
How PFE compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.7% is the 10th highest of 11, against a peer median of +8.5%.
- Free cash flow amounts to 17.2% of revenue for PFE, versus a peer median of 24.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $20.59B USD | +7.9% | +4.7% | 20.7% | |
| LTM Jun 2026 | $20.05B USD | +40048.0% | +24.9% | 25.2% | |
| LTM Jun 2026 | $18.21B USD | -0.2% | -9.8% | 28.3% | |
| LTM Jun 2026 | $16.06B USD | +9.1% | -5.6% | 24.2% | |
| LTM Jun 2026 | $15.82B USD | -5.9% | +13.8% | 28.4% | |
| LTM Jun 2026 | $13.2B USD | +40.9% | +4.3% | 43.3% | |
| LTM Jun 2026 | €11.77B EUR | +462.3% | +6.4% | 24.1% | |
| LTM Jun 2026 | $11.44B USD | -21.5% | +2.4% | 23.3% | |
| LTM Jun 2026 | $10.99B USD | -11.7% | -29.6% | 17.2% | |
| LTM Sep 2026 | $9.32B USD | -2.6% | +6.2% | 15.0% | |
| LTM Jun 2026 | £6.98B GBP | +49.6% | -4.8% | 21.0% | |
| Peer median (excluding PFE) | — | +8.5% | +4.5% | 24.1% | |
Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 22.46B | 31.4B | 2.17B | 8.05B | 7.79B |
| Depreciation & Amortization | 5.19B | 5.06B | 6.29B | 7.01B | 6.59B |
| Deferred Income Tax | (4.29B) | (3.76B) | (3.44B) | (2.1B) | (2.13B) |
| Stock-Based Compensation | 1.18B | 872M | 525M | 877M | 799M |
| Change in Working Capital | 12.8B | (4.46B) | (2.17B) | (3.07B) | (5.35B) |
| Accounts Receivables | (3.81B) | 261M | 347M | (109M) | (263M) |
| Inventory | (1.13B) | 592M | (1.17B) | (854M) | 561M |
| Accounts Payables | 1.24B | 1.19B | (300M) | (1.02B) | (469M) |
| Other Working Capital | 16.5B | (6.5B) | (1.05B) | (1.08B) | (5.18B) |
| Other Non-Cash Items | (4.76B) | 150M | 5.33B | 1.97B | 4.01B |
| Operating Cash Flow | 32.58B | 29.27B | 8.7B | 12.74B | 11.71B |
| Capital Expenditures | (2.71B) | (3.24B) | (3.91B) | (2.91B) | (2.63B) |
| Acquisitions (Net) | (12M) | (23B) | (43.43B) | 7.04B | (6.93B) |
| Purchases of Investments | (47.61B) | (38.78B) | (31.18B) | (10.31B) | (14.65B) |
| Sales of Investments | 28.1B | 45.46B | 46.42B | 8.83B | 22.69B |
| Other Investing Activities | (306M) | 3.77B | (180M) | 0 | 165M |
| Investing Cash Flow | (22.55B) | (15.78B) | (32.28B) | 2.65B | (1.35B) |
| Debt Repayment | (1.1B) | (3.52B) | 35.95B | (7.16B) | (74M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2B) | 0 | 0 | 0 |
| Dividends Paid | (8.73B) | (8.98B) | (9.25B) | (9.51B) | (9.77B) |
| Other Financing Activities | 16M | (335M) | (632M) | (469M) | (459M) |
| Financing Cash Flow | (9.82B) | (14.83B) | 26.07B | (17.14B) | (10.3B) |
| Effect of Forex Changes | (60M) | (165M) | (40M) | (66M) | 49M |
| Net Change in Cash | 158M | (1.52B) | 2.45B | (1.81B) | 99M |
| Free Cash Flow | 29.87B | 26.03B | 4.79B | 9.84B | 9.08B |
Pfizer Inc.
NYSE:PFE
Intrinsic Alpha fair value
Locked
Current Price
$28.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.